Bristol Myers Squibb (CELG-RI) Depreciation & Amortization (CF) (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has 18 years of Depreciation & Amortization (CF) data on file, last reported at $594.0 million in Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $594.0 million, down 41.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.6 billion (down 55.53% YoY), and the FY2025 annual result was $4.0 billion, down 58.22% from the prior year.
• Depreciation & Amortization (CF) slipped to $594.0 million in Q1 2026 per CELG-RI's latest filing, from $977.0 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $2.6 billion in Q2 2024 and troughed at $594.0 million in Q1 2026.
• A 5-year average of $2.0 billion and a median of $2.4 billion in 2023 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2024 and 2025: Depreciation & Amortization (CF) climbed 6.74% in 2024, then sank 61.06% in 2025.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $2.5 billion in 2022, then declined by 2.26% to $2.5 billion in 2023, then dropped by 23.7% to $1.9 billion in 2024, then tumbled by 48.03% to $977.0 million in 2025, then sank by 39.2% to $594.0 million in 2026.
• Business Quant data shows CELG-RI's Depreciation & Amortization (CF) at $594.0 million in Q1 2026, $977.0 million in Q4 2025, and $1.0 billion in Q3 2025.